AAAAAA

   
Results: 1-16 |
Results: 16
Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals - Two randomised, controlled trials
Authors: Noveck, RJ Laurent, A Kuss, M Talwalker, S Hubbard, RC
Citation: Rj. Noveck et al., Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals - Two randomised, controlled trials, CLIN DRUG I, 21(7), 2001, pp. 465-476
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
Authors: Harris, SI Kuss, M Hubbard, RC Goldstein, JL
Citation: Si. Harris et al., Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo, CLIN THER, 23(9), 2001, pp. 1422-1428
A double-blind, randomized comparison of intramuscularly and intravenouslyadministered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
Authors: Daniels, SE Grossman, EH Kuss, ME Talwalker, S Hubbard, RC
Citation: Se. Daniels et al., A double-blind, randomized comparison of intramuscularly and intravenouslyadministered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model, CLIN THER, 23(7), 2001, pp. 1018-1031
Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
Authors: Williams, GW Hubbard, RC Yu, SS Zhao, W Geis, GS
Citation: Gw. Williams et al., Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee, CLIN THER, 23(2), 2001, pp. 213-227
A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects
Authors: Karim, A Laurent, A Slater, ME Kuss, ME Qian, J Crosby-Sessoms, SL Hubbard, RC
Citation: A. Karim et al., A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects, J CLIN PHAR, 41(10), 2001, pp. 1111-1119
The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively
Authors: Desjardins, PJ Grossman, EH Kuss, ME Talwalker, S Dhadda, S Baum, D Hubbard, RC
Citation: Pj. Desjardins et al., The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively, ANESTH ANAL, 93(3), 2001, pp. 721-727
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
Authors: Goldstein, JL Correa, P Zhao, WW Burr, AM Hubbard, RC Verburg, KM Geis, GS
Citation: Jl. Goldstein et al., Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis, AM J GASTRO, 96(4), 2001, pp. 1019-1027
Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib - A randomized, controlled trial
Authors: Williams, GW Ettlinger, RE Ruderman, EM Hubbard, RC Lonien, ME Yu, SS Zhao, W Geis, GS
Citation: Gw. Williams et al., Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib - A randomized, controlled trial, JCR-J CLIN, 6(2), 2000, pp. 65-74
Celecoxib, a specific COX-2 inhibitor, has no significant effect on MTX pharmacokinetics or renal clearance in patients with RA (vol 26, pg 2539, 1999)
Authors: Karim, A Tolbert, DS Hunt, TL Hubbard, RC Harper, KM Geis, GS
Citation: A. Karim et al., Celecoxib, a specific COX-2 inhibitor, has no significant effect on MTX pharmacokinetics or renal clearance in patients with RA (vol 26, pg 2539, 1999), J RHEUMATOL, 27(2), 2000, pp. 557-557
Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects
Authors: Karim, A Tolbert, D Piergies, A Hubbard, RC Harper, K Wallemark, CB Slater, M Geis, GS
Citation: A. Karim et al., Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects, J CLIN PHAR, 40(6), 2000, pp. 655-663
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
Authors: Leese, PT Hubbard, RC Karim, A Isakson, PC Yu, SS Geis, GS
Citation: Pt. Leese et al., Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial, J CLIN PHAR, 40(2), 2000, pp. 124-132
Reduced risk of upper gastrointestinal ulcer complications with celecoxib a novel COX-2 inhibitor
Authors: Goldstein, JL Silverstein, FE Agrawal, NM Hubbard, RC Kaiser, J Maurath, CJ Verburg, KM Geis, GS
Citation: Jl. Goldstein et al., Reduced risk of upper gastrointestinal ulcer complications with celecoxib a novel COX-2 inhibitor, AM J GASTRO, 95(7), 2000, pp. 1681-1690
Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
Authors: Karim, A Tolbert, DS Hunt, TL Hubbard, RC Harper, KM Geis, GS
Citation: A. Karim et al., Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis, J RHEUMATOL, 26(12), 1999, pp. 2539-2543
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison
Authors: Emery, P Zeidler, H Kvien, TK Guslandi, M Naudin, R Stead, H Verburg, KM Isakson, PC Hubbard, RC Geis, GS
Citation: P. Emery et al., Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison, LANCET, 354(9196), 1999, pp. 2106-2111
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomized controlled trial
Authors: Simon, LS Weaver, AL Graham, DY Kivitz, AJ Lipsky, PE Hubbard, RC Isakson, PC Verburg, KM Yu, SS Zhao, WW Geis, GS
Citation: Ls. Simon et al., Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomized controlled trial, J AM MED A, 282(20), 1999, pp. 1921-1928
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
Authors: Bensen, WG Fiechtner, JJ McMillen, JI Zhao, WW Yu, SS Woods, EM Hubbard, RC Isakson, PC Verburg, KM Geis, GS
Citation: Wg. Bensen et al., Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial, MAYO CLIN P, 74(11), 1999, pp. 1095-1105
Risultati: 1-16 |